Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.

Wang, M; Han, X H; Zhang, L; Yang, J; Qian, J F; Shi, Y K; Kwak, L W; Romaguera, J; Yi, Q

Wang, M; Han, X H; Zhang, L; Yang, J; Qian, J F; Shi, Y K; Kwak, L W; Romaguera, J; Yi, Q.

Affiliation

Wang M; Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

Leukemia ; 22(1): 179-85, 2008 Jan.

Article in En | MEDLINE | ID: mdl-17898787

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Apoptosis/drug effects; Lymphoma, Mantle-Cell/pathology; Animals; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal, Murine-Derived; Blotting, Western; Boronic Acids/administration & dosage; Bortezomib; Caspases/metabolism; Cell Proliferation; Cyclophosphamide/administration & dosage; Drug Synergism; Immunophenotyping; In Vitro Techniques; Lymphoma, Mantle-Cell/drug therapy; Male; Mice; Mice, SCID; Poly(ADP-ribose) Polymerases/metabolism; Pyrazines/administration & dosage; Rituximab; Survival Rate; Transplantation, Heterologous

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Apoptosis / Lymphoma, Mantle-Cell Limits: Animals Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2008 Document type: Article Affiliation country: United States Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links